100 related articles for article (PubMed ID: 3390288)
1. Cytophotometric determination of DNA in mesotheliomas and reactive mesothelial cells.
Hafiz MA; Becker RL; Mikel UV; Bahr GF
Anal Quant Cytol Histol; 1988 Apr; 10(2):120-6. PubMed ID: 3390288
[TBL] [Abstract][Full Text] [Related]
2. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
Friedman MT; Gentile P; Tarectecan A; Fuchs A
Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
[TBL] [Abstract][Full Text] [Related]
3. A study on the mesothelial cell kinetics in pleural effusions by DNA cytophotometry and autoradiography with tritiated thymidine.
Isoda K; Kim H; Hamamoto Y
Acta Pathol Jpn; 1984 Jul; 34(4):775-83. PubMed ID: 6485796
[TBL] [Abstract][Full Text] [Related]
4. Image cytometry: an aid for cytological diagnosis of pleural effusions.
Osterheld MC; Liette C; Anca M
Diagn Cytopathol; 2005 Mar; 32(3):173-6. PubMed ID: 15690335
[TBL] [Abstract][Full Text] [Related]
5. The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions.
Illei PB; Ladanyi M; Rusch VW; Zakowski MF
Cancer; 2003 Feb; 99(1):51-6. PubMed ID: 12589646
[TBL] [Abstract][Full Text] [Related]
6. Cytopathology of malignant mesothelioma: a stepwise logistic regression analysis.
Stevens MW; Leong AS; Fazzalari NL; Dowling KD; Henderson DW
Diagn Cytopathol; 1992; 8(4):333-41. PubMed ID: 1638933
[TBL] [Abstract][Full Text] [Related]
7. Cytopathologic differential diagnosis of malignant mesothelioma, adenocarcinoma and reactive mesothelial cells: A logistic regression analysis.
Cakir E; Demirag F; Aydin M; Unsal E
Diagn Cytopathol; 2009 Jan; 37(1):4-10. PubMed ID: 18973123
[TBL] [Abstract][Full Text] [Related]
8. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids.
Politi E; Kandaraki C; Apostolopoulou C; Kyritsi T; Koutselini H
Diagn Cytopathol; 2005 Mar; 32(3):151-5. PubMed ID: 15690338
[TBL] [Abstract][Full Text] [Related]
9. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
[TBL] [Abstract][Full Text] [Related]
10. Quantitative and qualitative differences between benign and malignant mesothelial cells in pleural fluid.
Kwee WS; Veldhuizen RW; Alons CA; Morawetz F; Boon ME
Acta Cytol; 1982; 26(4):401-6. PubMed ID: 6957089
[TBL] [Abstract][Full Text] [Related]
11. Cytogenetic analysis of effusions from malignant mesothelioma. A diagnostic adjunct to cytology.
Granados R; Cibas ES; Fletcher JA
Acta Cytol; 1994; 38(5):711-7. PubMed ID: 8091903
[TBL] [Abstract][Full Text] [Related]
12. Freeze-fracture study of intercellular junctions in benign and malignant mesothelial cells in effusions and a comparison with those seen in pleural mesotheliomas (solid tumour).
Mukherjee TM; Swift JG; Henderson DW
J Submicrosc Cytol Pathol; 1988 Jan; 20(1):195-208. PubMed ID: 3370618
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical expression of osteopontin in epithelioid mesotheliomas and reactive mesothelial proliferations.
Tigrani DY; Weydert JA
Am J Clin Pathol; 2007 Apr; 127(4):580-4. PubMed ID: 17369133
[TBL] [Abstract][Full Text] [Related]
14. Multiparameter flow cytometric DNA analysis of effusions: a prospective study of 36 cases compared with routine cytology and immunohistochemistry.
Joseph MG; Banerjee D; Harris P; Gibson S; McFadden RG
Mod Pathol; 1995 Aug; 8(6):686-93. PubMed ID: 8532707
[TBL] [Abstract][Full Text] [Related]
15. The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions.
Hasteh F; Lin GY; Weidner N; Michael CW
Cancer Cytopathol; 2010 Apr; 118(2):90-6. PubMed ID: 20209622
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of AgNOR count in distinguishing benign from malignant mesothelial cells in pleural fluids.
Colecchia M; Leopardi O
Pathol Res Pract; 1992 Jun; 188(4-5):541-4. PubMed ID: 1409085
[TBL] [Abstract][Full Text] [Related]
17. The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions.
Geyer SJ
Cancer Cytopathol; 2010 Aug; 118(4):225; author reply 225. PubMed ID: 20731007
[No Abstract] [Full Text] [Related]
18. Quantitative ultrastructural study of nuclei from exfoliated benign and malignant mesothelial cells and metastatic adenocarcinoma cells.
Dardick I; Butler EB; Dardick AM
Acta Cytol; 1986; 30(4):379-84. PubMed ID: 3461648
[TBL] [Abstract][Full Text] [Related]
19. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions.
Bassarova AV; Nesland JM; Davidson B
Am J Surg Pathol; 2006 Jul; 30(7):878-82. PubMed ID: 16819331
[TBL] [Abstract][Full Text] [Related]
20. Expression of the nerve growth factor receptors TrkA and p75 in malignant mesothelioma.
Davidson B; Reich R; Lazarovici P; Flørenes VA; Risberg B; Nielsen S; Sert B; Bedrossian C
Lung Cancer; 2004 May; 44(2):159-65. PubMed ID: 15084380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
